BMN 673 (BioDeep_00000760239)
代谢物信息卡片
化学式: C19H14F2N6O (380.1197)
中文名称: 5-氟-8-(4-氟苯基)-2,7,8,9-四氢-9-(1-甲基-1H-1,2,4-噻唑-5-基)-3H-吡啶并[4,3,2-de]二氮杂萘-3-酮
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1C(=NC=N1)C2C(NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F
InChI: InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)
描述信息
D000970 - Antineoplastic Agents > D000067856 - Poly(ADP-ribose) Polymerase Inhibitors
D004791 - Enzyme Inhibitors
同义名列表
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
亚细胞结构定位 | 关联基因列表 |
---|
文献列表
- Cen Guo, Yanke Yu, Jayeta Chakrabarti, Sarina A Piha-Paul, Rebecca Moroose, Anna Plotka, Haihong Shi, Chandrasekar Durairaj, Diane D Wang, Zev A Wainberg. Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment.
British journal of clinical pharmacology.
2022 07; 88(7):3392-3403. doi:
10.1111/bcp.15294
. [PMID: 35236002] - Meng-Zhu Li, Tao Meng, Shan-Shan Song, Xu-Bin Bao, Lan-Ping Ma, Ning Zhang, Ting Yu, Yong-Liang Zhang, Bing Xiong, Jing-Kang Shen, Ze-Hong Miao, Jin-Xue He. Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers.
Investigational new drugs.
2021 10; 39(5):1213-1221. doi:
10.1007/s10637-021-01096-4
. [PMID: 33710464] - Chandrasekar Durairaj, Jayeta Chakrabarti, Cristiano Ferrario, Holger W Hirte, Sunil Babu, Sarina A Piha-Paul, Anna Plotka, Justin Hoffman, Haihong Shi, Diane D Wang. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors.
Clinical pharmacokinetics.
2021 07; 60(7):921-930. doi:
10.1007/s40262-020-00983-y
. [PMID: 33686631] - Sara M Federico, Alberto S Pappo, Natasha Sahr, April Sykes, Olivia Campagne, Clinton F Stewart, Michael R Clay, Armita Bahrami, Mary B McCarville, Sue C Kaste, Victor M Santana, Sara Helmig, Jessica Gartrell, Anang Shelat, Rachel C Brennan, Dana Hawkins, Kimberly Godwin, Michael W Bishop, Wayne L Furman, Elizabeth Stewart. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.
European journal of cancer (Oxford, England : 1990).
2020 09; 137(?):204-213. doi:
10.1016/j.ejca.2020.06.014
. [PMID: 32795876] - Gamze Guney Eskiler, Gulsah Cecener, Unal Egeli, Berrin Tunca. Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer.
Journal of cellular physiology.
2020 09; 235(9):6230-6245. doi:
10.1002/jcp.29552
. [PMID: 32017076] - Christopher L Heidler, Eva K Roth, Markus Thiemann, Claudia Blattmann, Ramon L Perez, Peter E Huber, Michal Kovac, Beate Amthor, Gabriele Neu-Yilik, Andreas E Kulozik. Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib.
International journal of cancer.
2020 08; 147(4):1059-1070. doi:
10.1002/ijc.32814
. [PMID: 31782150] - Yan Jia, Huanhuan Jin, Liyuan Gao, Xiang Yang, Feixia Wang, Hai Ding, Anping Chen, Shanzhong Tan, Feng Zhang, Jiangjuan Shao, Shijun Wang, Shizhong Zheng. A novel lncRNA PLK4 up-regulated by talazoparib represses hepatocellular carcinoma progression by promoting YAP-mediated cell senescence.
Journal of cellular and molecular medicine.
2020 05; 24(9):5304-5316. doi:
10.1111/jcmm.15186
. [PMID: 32243714] - Mohamed Elmeliegy, István Láng, Elena A Smolyarchuk, Chin-Hee Chung, Anna Plotka, Haihong Shi, Diane Wang. Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours.
British journal of clinical pharmacology.
2020 04; 86(4):771-778. doi:
10.1111/bcp.14178
. [PMID: 31770456] - Sara A Hurvitz, Anthony Gonçalves, Hope S Rugo, Kyung-Hun Lee, Louis Fehrenbacher, Lida A Mina, Sami Diab, Joanne L Blum, Jayeta Chakrabarti, Mohamed Elmeliegy, Liza DeAnnuntis, Eric Gauthier, Akos Czibere, Iulia Cristina Tudor, Ruben G W Quek, Jennifer K Litton, Johannes Ettl. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
The oncologist.
2020 03; 25(3):e439-e450. doi:
NULL
. [PMID: 32162822] - Yanke Yu, Chandrasekar Durairaj, Haihong Shi, Diane D Wang. Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer.
Journal of clinical pharmacology.
2020 02; 60(2):218-228. doi:
10.1002/jcph.1520
. [PMID: 31489639] - Lei Ye, Jingjing Chen, Shuang-Long Li, Yong-Liang Zhu, Saili Xie, Xiaoxiang Du. UPLC-MS/MS method for the determination of talazoparib in rat plasma and its pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2020 Jan; 177(?):112850. doi:
10.1016/j.jpba.2019.112850
. [PMID: 31499430] - Mohamed W Attwa, Adnan A Kadi, Ali S Abdelhameed, Hassan A Alhazmi. Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies.
Drug design, development and therapy.
2020; 14(?):783-793. doi:
10.2147/dddt.s239458
. [PMID: 32158196] - Yanke Yu, Chin-Hee Chung, Anna Plotka, Kevin Quinn, Haihong Shi, Zsuzsanna Pápai, Linh Nguyen, Diane Wang. A Phase 1 Mass Balance Study of 14 C-Labeled Talazoparib in Patients With Advanced Solid Tumors.
Journal of clinical pharmacology.
2019 09; 59(9):1195-1203. doi:
10.1002/jcph.1415
. [PMID: 30964553] - Justin Hoffman, Jayeta Chakrabarti, Anna Plotka, Adriana Milillo Naraine, David Kanamori, Rebecca Moroose, Linh Nguyen, Diane Wang, Zev A Wainberg. Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors.
Anti-cancer drugs.
2019 06; 30(5):523-532. doi:
10.1097/cad.0000000000000772
. [PMID: 30875341] - Gamze Guney Eskiler, Gulsah Cecener, Gokhan Dikmen, Unal Egeli, Berrin Tunca. Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro.
Current drug delivery.
2019; 16(6):511-529. doi:
10.2174/1567201816666190515105532
. [PMID: 31113350] - Gamze Guney Eskiler, Gulsah Cecener, Unal Egeli, Berrin Tunca. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Pharmaceutical research.
2018 Sep; 35(11):218. doi:
10.1007/s11095-018-2502-6
. [PMID: 30255456] - Yunhua Liu, Hanchen Xu, Kevin Van der Jeught, Yujing Li, Sheng Liu, Lu Zhang, Yuanzhang Fang, Xinna Zhang, Milan Radovich, Bryan P Schneider, Xiaoming He, Cheng Huang, Chi Zhang, Jun Wan, Guang Ji, Xiongbin Lu. Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.
The Journal of clinical investigation.
2018 07; 128(7):2951-2965. doi:
10.1172/jci98727
. [PMID: 29649003] - Mahendra Kumar Hidau, Srikanth Kolluru, Srinath Palakurthi. Development and validation of a high-performance liquid chromatography method for the quantification of talazoparib in rat plasma: Application to plasma protein binding studies.
Biomedical chromatography : BMC.
2018 Feb; 32(2):. doi:
10.1002/bmc.4046
. [PMID: 28677821] - Sani H Kizilbash, Shiv K Gupta, Kenneth Chang, Ryo Kawashima, Karen E Parrish, Brett L Carlson, Katrina K Bakken, Ann C Mladek, Mark A Schroeder, Paul A Decker, Gaspar J Kitange, Yuqiao Shen, Ying Feng, Andrew A Protter, William F Elmquist, Jann N Sarkaria. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
Molecular cancer therapeutics.
2017 Dec; 16(12):2735-2746. doi:
10.1158/1535-7163.mct-17-0365
. [PMID: 28947502]